How Immunotherapy Unmasks Invisible Lung Cancer

Usually when you think about getting sick, it's, um, it's like an invasion, right?

CO-HOST: Yeah, exactly. Like a virus breaches the walls.

Right, the biological alarms start blaring and your immune system just rushes in to fight it. It's this loud, chaotic, microscopic battlefield.

CO-HOST: A total war zone in your bloodstream.

Exactly. But cancer is terrifying precisely because it isn't a foreign invader at all. It's an inside job.

CO-HOST: It really is, it's your own cells just, you know, corrupted, flying completely under the radar.

There are no alarms, no battlefield, just this quiet, invisible expansion.

CO-HOST: It's the ultimate biological stealth mode. And, I mean, for decades our only real response in oncology was to, essentially, uh, carpet bomb the entire area with chemotherapy.

Just hoping to hit the invisible target before, you know, causing too much collateral damage to the healthy tissue.

CO-HOST: Right, which was brutal.

But looking at this massive stack of sources today, I mean, we've got dense clinical trial data, biomarker analyses and some incredibly exciting late-breaking updates straight from ASCO 2026.

CO-HOST: The amount of data coming out is just staggering.

It really is. Welcome to today's deep dive everyone. We are exploring a true paradigm shift in advanced non-small cell lung cancer or NSCLC.

CO-HOST: We're talking about how doctors are literally retraining the immune system to see the invisible.

Yes, exactly. Our mission today is to cut through all the oncology jargon and look at when these modern treatments, these checkpoint inhibitors, when they actually work, when they fail, and how doctors use these specific biological markers to make complex life-or-death decisions.

CO-HOST: Because we've really moved past the era of just asking, you know, does this drug kill cancer? Now we're asking how do we manipulate the body's own regulatory systems to do the killing for us?

Right, and whether you are a science enthusiast or like a medical professional trying to catch up on the literature, or even someone navigating the healthcare system for yourself, you need to understand this.

CO-HOST: It dictates every choice made in a modern clinic.

Exactly. Understanding how we are selectively weaponizing the immune system is arguably one of the most fascinating scientific breakthroughs of our time. So, before we talk about the treatments themselves, let's talk about that stealth mode.

CO-HOST: Right. How the cancer hides.

Yeah, and the compass that doctors used to find it.

CO-HOST: So that compass is primarily a biomarker known as PDL1.

Okay.

CO-HOST: It's a protein, and its presence, or well, its absence on the surface of a tumor cell dictates the entire first line of therapy.

Okay, let's unpack this because the biology here is just incredible. Imagine your immune system's T-cells are like the bouncers at a very exclusive club, and the club is your body.

CO-HOST: That's a great way to think about it.

Right. Their entire job is to patrol the crowd, look for troublemakers and kick them out. But normal healthy cells need a way to protect themselves from getting kicked out by overzealous bouncers.

CO-HOST: They need an ID card.

Exactly. They have a specific protein on their surface. It's basically an ID card that says, "Hey, I belong here, don't attack me."

CO-HOST: And that interaction is what we call an immune checkpoint. When the T-cell's receptor, which is called PD1, links up with that ID card, PDL1, it sends an inhibitory signal.

It tells the immune system to stand down.

CO-HOST: Right. It's a vital evolutionary safety mechanism. Because without it your immune system will just constantly attack your own organs. You'd have severe autoimmune diseases.

But tumors are sneaky, as they mutate, they figure out how to, you know, manufacture their own version of this ID card. They start coding themselves in PDL1.

CO-HOST: So when the T-cell bouncer walks up to the mutated cancer cell, totally ready to destroy it.

The cancer cell just flashes this fake ID, the bouncer scans it, that inhibitory signal is sent, and the bouncer just walks right past.

CO-HOST: The cancer gets to stay in the club and multiply.

Exactly. And checkpoint inhibitors, these immunotherapy drugs we're talking about, they essentially confiscate that fake ID. They act like molecular tape, right? Covering up the scanner so the handshake can't happen.

CO-HOST: And the bouncers finally recognize the cancer for the threat it is and attack. What's fascinating here is this sheer magnitude of the survival curves when you successfully block that interaction.

Yeah, the numbers are wild.

CO-HOST: If we look at the foundational data, specifically the KEYNOTE-024 trial, it fundamentally altered the trajectory of lung cancer treatment.

Okay, walk us through it.

CO-HOST: They isolated patients with advanced lung cancer whose tumors were covered in these fake IDs. We measure this using a tumor proportion score, or TPS.

Okay, TPS.

CO-HOST: Right. This trial focused on patients with a TPS of 50% or greater.

Meaning at least half of the biopsied cancer cells were heavily expressing this PDL1 fake ID.

CO-HOST: Exactly. And they gave these patients a checkpoint inhibitor called pembrolizumab instead of the standard chemotherapy.

And looking at the five-year survival data in our notes, I mean, it's a milestone. At the five-year mark, the overall survival rate was 31.9% for the immunotherapy group.

CO-HOST: Compared to just 16.3% for the chemotherapy group.

Nearly a third of patients with metastatic lung cancer alive at five years. That was unthinkable a decade ago. It established single-agent immunotherapy as the definitive standard of care for that high-expressing group.

I have to push back here though.

CO-HOST: Oh?

Because going through the broader biomarker analyses in our stack of sources, this PDL1 compass seems, well, deeply flawed.

CO-HOST: It's definitely not perfect.

Right, because the guidelines treat this tumor proportion score like a hard regulatory cutoff. You hit 50%, you get the drug. But the data shows PDL1 expression is highly variable, right?

CO-HOST: Extremely variable, yes.

It can differ between two biopsies taken from the exact same tumor. It shifts over time. And worst of all, some patients with a massive score, like 90%, show primary resistance.

CO-HOST: They don't respond to the drug at all.

Exactly. If it's this messy, why is it still our gold standard?

CO-HOST: Well, you're pointing out the central frustration of modern thoracic oncology right now. We are taking a highly dynamic biological continuum and forcing it into a binary yes or no bucket just for regulatory convenience.

Which seems risky.

CO-HOST: It's undeniably messy. I mean, a needle biopsy only captures a tiny fraction of the tumor, right? You might sample a hotspot of PDL1 or a completely cold zone.

So why keep using it?

CO-HOST: From a purely pragmatic standpoint, nothing else has consistently proven to be a better predictive tool in large-scale Phase 3 trials.

Okay, but what about tumor mutational burden? I saw the IMpower110 trial heavily featured in the ASCO updates, focusing on like how mutated the tumor is rather than just looking for the fake ID.

CO-HOST: Right, the biological logic behind tumor mutational burden, or TMB, is actually incredibly elegant.

How so?

CO-HOST: Well, if a tumor has hundreds of genetic mutations, it should look wildly foreign to the body. Those mutations create malformed proteins called neoantigens.

And the more neoantigens, the more targets for the T-cells to lock onto.

CO-HOST: Exactly. And IMpower110 showed that highly mutated tumors do derive a lot of benefit from immunotherapy.

So what's the catch?

CO-HOST: The bottleneck is real-world application. TMB is just clunky to measure. There's a severe lack of standardization across different genomic sequencing platforms. One lab's high TMB is another lab's intermediate.

Oh, I see. So it hasn't dethroned PDL1 because we can't agree on how to measure it reliably.

CO-HOST: Exactly.

Though, looking at the ASCO 2026 data, there does seem to be a push toward more sophisticated tools to replace it eventually.

CO-HOST: Yes, things like RNA-based immune signatures that look at the entire neighborhood around the tumor.

Or tracking circulating tumor DNA, ctDNA in the blood to see if the cancer is shedding DNA in real time.

CO-HOST: But for now, that PDL1 stain on a biopsy slide remains the gatekeeper.

And there's a massive life or death caveat to that gatekeeper, isn't there?

CO-HOST: A huge one. A patient's tumor can have a PDL1 score of 100%. But if that same tumor also harbors a specific driver mutation, like an alteration in the EGFR or ALK genes, giving them immunotherapy is a grave clinical error.

Wow. Okay, driver mutations dictate therapy choices over PDL1 status.

CO-HOST: Always.

I want to make sure the mechanics of that are clear for everyone listening. If the tumor is flashing the fake ID, why wouldn't confiscating it with immunotherapy work?

CO-HOST: Because the underlying biology of the tumor is fundamentally different. In a tumor with an EGFR mutation, the cancer isn't primarily relying on immune evasion to survive.

What's it doing instead?

CO-HOST: It's being driven by a broken genetic switch that's permanently stuck in the on position. It's constantly signaling the cell to divide and conquer, the immune system is just a secondary player there.

Oh, wow.

CO-HOST: So if you give those patients immunotherapy instead of a targeted therapy, like a pill, say osimertinib, that enters the cell and physically jams that broken switch into the off position, the patient will progress rapidly.

So, if a young patient or, you know, someone with no smoking history, has a biopsy come back with sky-high PDL1, their oncology team cannot just blindly hand them a checkpoint inhibitor.

CO-HOST: Absolutely not. They must run comprehensive next-generation sequencing, or NGS, to map the entire genome of that tumor first.

It's an absolute requirement.

CO-HOST: Yes. And the danger isn't just that the immunotherapy is ineffective for those patients. These drugs stay in the body for months. If you start a patient on a checkpoint inhibitor, realize it isn't working, and then pivot to the targeted EGFR pill, the overlapping mechanisms in the liver and lungs frequently trigger severe, sometimes fatal, toxicities.

You have to get the sequence right the very first time.

CO-HOST: You really do.

Okay. So, that covers the patients who have the high PDL1 fake ID, or those with specific genetic mutations. But what about the vast majority of patients?

CO-HOST: Right.

Building directly on how unreliable PDL1 can be, what if a patient's score is low, like under 50%?

CO-HOST: Or what if their disease is so aggressive and symptomatic that doctors don't have the luxury of waiting to see if the immune system slowly wakes up?

Exactly. How do we force the tumor out of hiding?

CO-HOST: We escalate. We move from monotherapy to combination regimens. Specifically, combining traditional chemotherapy with immunotherapy.

Which on the surface sounds entirely counterintuitive, right? I mean, chemotherapy notoriously suppresses the immune system by wiping out white blood cells.

CO-HOST: It does.

Why would you give an immune-suppressing drug at the exact same time you're trying to activate the immune system?

CO-HOST: It's a great question.

I like to think of chemotherapy here not as a systemic poison, but as a flare gun. If the tumor isn't showing enough fake IDs, the bouncer T-cells are just standing around in the dark.

CO-HOST: Right.

Giving the patient chemotherapy shoots a flare gun right into the tumor microenvironment.

CO-HOST: You're referring to immunogenic cell death.

Exactly.

CO-HOST: When the chemotherapy hits the tumor, it doesn't just quietly dissolve the cancer cells. It violently ruptures them.

Spilling their internal contents, their mutated DNA, and their proteins all over the surrounding tissue.

CO-HOST: Yes, it creates so much sudden biological debris and chaos that the T-cells are forced to look.

The flare gun illuminates the targets. It sensitizes the area. So when you simultaneously drop in the checkpoint inhibitor to block whatever PDL1 is there, the immune system is already primed, aggregated, and ready to attack.

CO-HOST: And the clinical data validates that aggressive approach beautifully. If we look at the KEYNOTE-189 trial for non-squamous lung cancer, patients received pembrolizumab alongside standard platinum pemetrexed chemotherapy.

Okay, and the results.

CO-HOST: The median overall survival hit 22 months, compared to just 10.7 months for the patients who only received chemotherapy.

It effectively doubled survival.

CO-HOST: It did. And we saw the same paradigm shift in the KEYNOTE-407 trial for squamous cell lung cancer.

Wow.

CO-HOST: The critical takeaway from these chemoimmunotherapy combinations is that they are PDL1 agnostic.

Because of that flare gun effect.

CO-HOST: Exactly. The baseline PDL1 score, whether it was 1% or 0%, it didn't restrict the patients from benefiting.

But I mean, long-term chemotherapy is brutal on the human body. There has to be a way to achieve that massive immune activation without relying on months of toxic chemo infusions, right?

CO-HOST: If we connect this to the bigger picture where the field is heading, researchers are aggressively trying to spare patients from chemotherapy.

Oh, hey, how?

CO-HOST: The CHECKMATE 9LA trial attempted a compromise. They used just two cycles of chemotherapy, a very brief primer, just to shoot off that initial flare, and combined it with two different immunotherapy drugs. Nivolumab and Ipilimumab.

Two checkpoint inhibitors at the exact same time.

CO-HOST: Yes.

We've talked about blocking PD1, the local bouncer. What is the second drug doing?

CO-HOST: Ipilimumab blocks a completely different checkpoint called CTLA4.

Okay.

CO-HOST: While PD1 acts locally at the site of the tumor, CTLA4 acts earlier in the immune cycle, deep in the lymph nodes where T-cells are generated. It acts like a master brake on the entire immune system.

Oh, wow. So when you block CTLA4 alongside PD1, you aren't just taking the blinders off the bouncers at the club.

CO-HOST: Right.

You are unleashing an army of newly trained, highly aggressive T-cells from the barracks.

CO-HOST: Exactly. And the CHECKMATE-227 trial took this even further, dropping the chemotherapy entirely and just using that dual checkpoint blockade.

But, you know, there is no free lunch in human biology. If you remove the master brakes in the lymph nodes and the local brakes at the tumor, the risk of friendly fire has to skyrocket, doesn't it?

CO-HOST: Oh, absolutely. The toxicity profile shifts dramatically. You see a significant increase in severe immune-mediated adverse events.

Because the immune system is hyper-activated.

CO-HOST: Exactly. It starts attacking healthy organs. We see severe colitis in the gut, pneumonitis in the lungs, and hepatitis in the liver.

That's terrifying.

CO-HOST: It is. A major theme across the AF core ASCO 2026 panels is toxicity management. Oncology teams are essentially having to become expert rheumatologists and gastroenterologists just to manage these newly induced autoimmune conditions so patients can stay on the life-saving therapies.

Here's where it gets really interesting though. Because as much as the field wants to just combine different checkpoint inhibitors to replace chemo, our sources show a graveyard of failed trials.

CO-HOST: Yes, quite a few.

You can't just throw multiple immune-activating drugs at lung cancer and expect a synergistic miracle. The notes detail several drugs targeting novel checkpoints like TIGIT in the SKYSCRAPER-01 trial or LAG-3.

CO-HOST: Right.

These targets showed immense promise in other cancers, particularly melanoma, but they largely failed to improve survival in Phase 3 lung cancer trials. Why is lung cancer such a stubborn fortress?

CO-HOST: It really comes down to the architecture of the tumor microenvironment.

Okay, how so?

CO-HOST: Well, melanoma is often highly visible to the immune system. It sits on the skin, it's highly mutated by UV radiation, and is generally easier for T-cells to infiltrate.

And lung cancer?

CO-HOST: Lung cancer's microenvironment is notoriously immunosuppressive. The tumor actively secretes chemical signals that put T-cells to sleep or, even worse, turn them into regulatory cells that actually protect the tumor.

Oh, man.

CO-HOST: Yeah. Factor in the sheer heterogeneity of the disease where a single lung tumor might have wildly different genetic profiles from one edge of the mass to the other, often complicated by decades of smoking-induced DNA damage. And you have a fortress that easily deflects secondary checkpoint inhibitors.

But everything we've talked about so far is fighting a fire that is already out of control, right? It's advanced metastatic disease.

CO-HOST: Yes.

The real paradigm shift in these ASCO notes isn't just about managing the fire to prolong life. It's about putting it out before it spreads. And that means taking everything we just learned and moving it earlier in the timeline.

CO-HOST: Right. Moving into the perioperative setting.

The period immediately before and after surgical resection.

CO-HOST: It's exactly.

Where the goal shifts completely from, you know, managing a terminal diagnosis to actually curing the patient.

CO-HOST: And the data coming out of the perioperative space is nothing short of astounding.

Let's hear it.

CO-HOST: Let's look at the KEYNOTE-671 trial. They enrolled patients with early-stage tumors that were deemed surgically resectable.

Okay.

CO-HOST: Instead of just taking them straight to the operating room, they gave them pembrolizumab combined with chemotherapy first. That's the neoadjuvant phase.

So before the surgery.

CO-HOST: Yes. Then after the surgery, the patients continued receiving the immunotherapy alone. That's the adjuvant phase.

And the survival metrics really reflect that aggressive upfront approach, don't they?

CO-HOST: They do.

The event-free survival, which is the time patients live without the cancer returning, progressing, or causing death was 47.2 months compared to just 18.3 months for the control group.

CO-HOST: A massive difference.

Yeah. And the 24-month overall survival hovered near 80%. CHECKMATE-77T confirmed this identical approach using nivolumab.

CO-HOST: Right. Those long-term survival curves are critical. But the most immediate visceral feedback we get from these trials happens right in the pathology lab, right after the surgery.

Oh. This part is amazing.

CO-HOST: It's a metric called pathological complete response.

Right. So imagine you're going into surgery to remove a lung tumor. You've gone through your neoadjuvant rounds of immunotherapy and chemo. The surgeon successfully removes the mass, sends it down the hall to the pathologist.

CO-HOST: And the pathologist slices it open, puts it under the microscope and finds nothing.

The cancer is already completely dead. There are zero viable cancer cells left in the tissue.

CO-HOST: That is a pathological complete response, or PCR. In the CHECKMATE-77T trial, the neoadjuvant immunotherapy and chemo combination achieved a PCR of 25.3%.

Wow. A quarter of the patients.

CO-HOST: Yes. A quarter of the patients had no living tumor remaining at the exact moment the surgeon's scalpel hit the tissue.

A quarter of patients achieving total cellular death before surgery. I mean, it gives the patient and the medical team immediate, tangible proof that the microscopic disease is being eradicated, long before they have to wait years to track survival data.

CO-HOST: This raises an important question though, bringing us back to the biomarker discussion.

Okay.

CO-HOST: What about those driver mutations we talked about? The EGFR and ALK alterations where immunotherapy is biologically counterproductive. Do those rules still apply in this early surgical stage?

The data from the ADAURA trial answers that with a jaw-dropping yes. They looked at patients with Stage 3 lung cancer, so disease that had spread locally but wasn't fully metastatic.

CO-HOST: Right.

Critically, these patients all had that EGFR mutation, the broken genetic switch.

CO-HOST: Following standard chemoradiation instead of trying to stimulate the immune system with checkpoint inhibitors, the ADAURA trial gave these patients osimertinib.

The targeted pill designed to shut off that specific broken switch.

CO-HOST: Exactly. The progression-free survival for the patients receiving the targeted therapy was 39.1 months.

And to understand the magnitude of that, the control group receiving a placebo had a progression-free survival of just 5.6 months. The hazard ratio was 0.16.

CO-HOST: Which is incredible.

To strip away the statistical jargon, a hazard ratio of 0.16 essentially means that the patients taking the targeted pill experienced an 84% reduction in the risk of their cancer progressing or causing death compared to the placebo group.

CO-HOST: The progression curve basically flatlined. You almost never see an 84% risk reduction in oncology trials.

It completely rewrites the playbook for early-stage disease. It proves that aggressive upfront molecular testing is no longer just a luxury for advanced stage IV patients.

CO-HOST: It is a fundamental requirement for early-stage patients as well. You cannot afford to have a surgeon who just wants to cut, a radiation oncologist who just wants to radiate, and a medical oncologist siloed away.

Multidisciplinary tumor boards are mandatory.

CO-HOST: Absolutely. Everyone must be looking at the patient's genetic sequencing before the first intervention occurs.

So, what does this all mean? We have covered a tremendous amount of biological ground today.

CO-HOST: We really have.

If we distill the ASCO 2026 data down to its core, there are really three pillars defining the current state of lung cancer treatment. First, that PDL1 fake ID remains our primary, albeit imperfect, compass, but it is always subordinate to genomic testing for driver mutations.

CO-HOST: Yeah.

Second, for the majority of advanced patients without those mutations, combining the chemo flare gun with checkpoint inhibitors is the foundational workhorse.

CO-HOST: And third, the deployment of these immune-activating drugs into the perioperative setting, striking the cancer before and after surgery is actively redefining what a curable lung cancer diagnosis looks like.

Yeah.

CO-HOST: Furthermore, upcoming overall survival data from trials like IMpower010 will soon dictate if we give adjuvant immunotherapy to everyone after surgery or if we restrict it based on that messy PDL1 biomarker.

Knowledge is quite literally power in this landscape. Knowing that a single genetic mutation dictates your entire therapy pathway over your immune status is a detail that prevents catastrophic first-line treatment errors.

CO-HOST: It gives you the vocabulary to ask your medical team, have we run the next-generation sequencing? Do we know my molecular status before we start this infusion?

It moves the patient from being a passive recipient of care to an active participant in their treatment strategy.

CO-HOST: Absolutely.

And that brings us to the end of today's deep dive. But before we sign off, I want to leave you with a final lingering thought to ponder on your own.

CO-HOST: Okay.

We started this conversation talking about the invisible stealth mode of cancer and the cellular bouncers that patrol our bloodstreams. Today we are celebrating clinical trials achieving a 25% pathological complete response rate, total tumor death before the surgeon even operates.

CO-HOST: Which is phenomenal.

But as researchers continue to crack the code on that hostile immunosuppressive microenvironment. As they figure out how to force the other 75% of tumors to drop their fake IDs and face the immune system, will there come a day when pharmacological immune activation becomes so relentlessly effective that the surgical scalpel itself becomes obsolete in lung cancer?

CO-HOST: The data suggests it is a profound and increasingly plausible possibility.

Thank you so much for joining us on this deep dive into the ASCO 2026 updates. Keep questioning the consensus, keep learning the mechanics, and we'll catch you next time.